All In Biotech

Drug Trial Radar · NCT07869147

Study of ORJ-001 for the Treatment of IPF

A Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Tolerability (Part A), and Efficacy (Part B), of ORJ-001 in Patients With Idiopathic Pulmonary Fibrosis (ORBIT-IPF)

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

95

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Jan 2029

Study completion Mar 2029

Sponsor

Lead sponsor
Oorja Bio, Inc.Industry
Sponsor type
Industry
First posted
Oct 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ORJ-001 is a new class of drugs intended for the treatment of patients with idiopathic pulmonary fibrosis (IPF). This is a Phase 2 study in two parts; the objective of Part A will determine if ORJ-001 is well-tolerated by patients and how long the drug stays in the body. Part B will test how well the drug affects lung function. Animal models of IPF have shown that ORJ-001 can repair damaged lung tissue and improve markers of lung function.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • ORJ-001Drug

    ORJ-001 is a peptide agonist of β1 integrin administered by subcutaneous injection twice weekly. In Part A, dose levels are 200 mg and 400 mg. In Part B, a single dose level selected from Part A will be evaluated.

  • PlaceboOther

    Matching placebo administered by subcutaneous injection twice weekly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Safety and Tolerability of ORJ-001: Number of Participants with Treatment-Related Adverse Events (TEAEs)Time frame: From first dose through Safety Follow-up Visit, up to 12 weeks.
  2. Part A: Safety and Tolerability of ORJ-001: Severity of Treatment-Emergent Adverse Events (TEAEs)Time frame: From first dose through Safety Follow-up Visit, up to 12 weeks.
  3. Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Systolic Blood PressureTime frame: Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
  4. Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Body TemperatureTime frame: Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
  5. Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Heart RateTime frame: Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
  6. Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Respiratory RateTime frame: Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
  7. Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Oxygen SaturationTime frame: Baseline and each study visit through Safety Follow-up Visit, up to 12 weeks.
  8. Part A: Safety and Tolerability of ORJ-001: Change from Baseline in Corrected QT IntervalTime frame: Baseline, Week 4, Week 12, and Safety Follow-up Visit up to 12 weeks.
  9. Part B: Change from Baseline in Forced Vital Capacity (FVC)Time frame: Baseline to Week 12

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Innova Pharma Research, LLC

    Doral, Florida · Recruiting

  • Clinical Research Associates of Central PA

    DuBois, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.